Perspective · 10 Oct 2025
Research articlePublished 27 Feb 2025
Topical Magnesium- Coordinated Cannabidiolic Acid (CBDA) for the Treatment of Restless Leg Syndrome
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Topical Magnesium-Coordinated Cannabidiolic Acid (CBDA) for the Treatment of Restless Leg Syndrome Restless Leg Syndrome (RLS) is multifactorial disease state with many different potential pathophysiological mechanisms, which includes iron deficiency, dysfunctions from the cerebral cortex and spinal cord to mechanosensitive channels at the musculoskeletal periphery. Most therapeutic agents effectiveness focuses on the central nervous system (e.g., dopaminergic drugs) or Renshaw cells. There are virtually no effective therapeutic agents that are focused on the periphery. We hypothesize that treatment for RLS can focus on the peripheral musculoskeletal component of the disease, more specifically the mechanosensitive channels such as Piezo 2 and TRPA1. We conducted an open-label IRB-approved clinical trial using a proprietary topical preparation of our magnesium-coordinated CBDA to explore the responses to this novel treatment modality. We found a statistically and clinically significant improvement in restless leg symptoms and without any reported adverse effects.
Subjects
Pulmonology & RespiratoryAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Sleep Disorders & Therapy.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Sleep Disorders & Therapy
- SubjectPulmonology & Respiratory
- BylineArticles whose byline prints “Debra Kimless”
- BylineArticles whose byline prints “Thomas Piccariello”
- BylineArticles whose byline prints “Jabari Byrd”
